Compare Amgen, Inc. (AMGN) vs NIO Inc. (NIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs NIO Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while NIO Inc. trades at $4.85 (market cap $12.35B). The key difference: Amgen, Inc. is far larger — about 15.9× NIO Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| AMGN | NIO | |
|---|---|---|
Market Cap | $196.12B | $12.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $7.89 |
52-Week Low | $271.18 | $3.90 |
Enterprise Value | $241.41B | $11.59B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NIO trades at $4.78, unchanged on the day, with a bearish technical signal from moving averages. Revenue grew to $87.49B in 2025, but net losses persist at -$15.57B, though margins improved. Vehicle deliveries surged 62.9% year-over-year in June 2026, driven by strong ES9 performance. Cash flow remains negative, with a net cash outflow of -$10.87B in 2024.
The outlook is mixed: robust delivery growth and narrowing losses signal operational progress, but persistent cash burn and high debt pose risks. Analyst consensus leans bullish with 50% buy ratings, yet the stock faces headwinds from competitive pressures and macroeconomic concerns affecting Chinese EV stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
